Premium
Induction docetaxel and S‐1 followed by concomitant radiotherapy with low‐dose daily cisplatin in locally advanced head and neck carcinoma
Author(s) -
Kim Hye Ryun,
Lee Chang Geol,
Choi Eun Chang,
Kim Joo Hang,
Koh Yoon Woo,
Cho Byoung Chul
Publication year - 2016
Publication title -
head and neck
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.012
H-Index - 127
eISSN - 1097-0347
pISSN - 1043-3074
DOI - 10.1002/hed.24294
Subject(s) - docetaxel , medicine , induction chemotherapy , cisplatin , tolerability , chemotherapy , oncology , chemoradiotherapy , neutropenia , head and neck squamous cell carcinoma , head and neck cancer , radiation therapy , adverse effect
Background The purpose of this study was to assess the efficacy and safety of induction chemotherapy with docetaxel‐S‐1, and radiotherapy (RT) with concurrent daily cisplatin in locally advanced head and neck carcinoma. Method Fifty patients received 2 cycles of induction chemotherapy with induction chemotherapy with docetaxel and S‐1, followed by 7 cycles of RT with concurrent daily cisplatin. Results The most frequent grade 3 to 4 hematologic toxicity was neutropenia (14%). Forty of 50 patients who completed induction chemotherapy with docetaxel and S‐1 subsequently started RT with concurrent daily cisplatin, all within 3 to 4 weeks after the start of the second cycle of induction chemotherapy with docetaxel and S‐1. The best response to induction chemotherapy with docetaxel and S‐1 and after completion of RT with concurrent daily cisplatin was partial response (PR) in 52.5% and complete response in 47.5%, respectively. With a median follow‐up of 61 months, 5‐year progression‐free survival (PFS) and overall survival (OS) were 63.3% and 65.7%, respectively. Conclusion Administration of induction chemotherapy with docetaxel and S‐1 before RT with concurrent daily cisplatin chemoradiotherapy (CRT) resulted in a high response rate with good tolerability, and did not compromise subsequent CRT. © 2016 Wiley Periodicals, Inc. Head Neck 38 : E1653–E1659, 2016